VIVO Meridian stock Story

VIVO -  USA Stock  

USD 20.39  0.59  2.81%

As many of us are excited about healthcare space, it is fair to outline Meridian Bioscience. Why are we still confident in anticipation of a complete recovery. Is Meridian Bioscience valuation justified? Here I will cover 2020 perspective on the current valuation of the entity to give you a better outlook on taking a possible position in this stock.
Published over six months ago
View all stories for Meridian Bioscience | View All Stories
Is Meridian Bioscience well positioned for December economic uncertainties?
The company currently holds 106.24 M in liabilities with Debt to Equity (D/E) ratio of 0.46, which is about average as compared to similar companies. Meridian Bioscience has a current ratio of 3.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Meridian Bioscience is UNDERVALUED at 21.55 per share with modest projections ahead.
We determine the current worth of Meridian Bioscience using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Meridian Bioscience based exclusively on its fundamental and basic technical indicators. By analyzing Meridian Bioscience's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Meridian Bioscience's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Meridian Bioscience. We calculate exposure to Meridian Bioscience's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Meridian Bioscience's related companies.

Meridian Bioscience Investment Alerts

VIVO Meridian investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Meridian Bioscience performance across your portfolios.Please check all investment alerts for VIVO Meridian

Meridian Bioscience Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare VIVO Meridian value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Meridian Bioscience competition to find correlations between indicators driving the intrinsic value of VIVO Meridian.

How VIVO Meridian utilizes its cash?

To perform a cash flow analysis of Meridian Bioscience, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Meridian Bioscience is receiving and how much cash it distributes out in a given period. The Meridian Bioscience cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Meridian Bioscience Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at 38.76 Million

Sale by John Kenny of 30000 shares of Meridian Bioscience

Legal trades by Meridian Bioscience insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Meridian insider trading alert for sale of common stock by John Kenny, Chief Executive Officer, on 18th of March 2021. This event was filed by Meridian Bioscience Inc with SEC on 2021-03-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On Meridian Bioscience

The entity reported the previous year's revenue of 240.36 M. Net Income was 43.8 M with profit before overhead, payroll, taxes, and interest of 118.33 M.

Margins Breakdown

Meridian profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Meridian Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Meridian Bioscience profit margins.
Profit Margin
Operating Margin
Operating Margin24.03
EBITDA Margin29.09
Gross Margin71.72
Profit Margin16.72

Meridian Bioscience Revenue Per Employee is quite stable at the moment. Moreover, Meridian Bioscience Earnings Before Interest Taxes and Depreciation Amortization EBITDA is quite stable at the moment.

Will Meridian Bioscience latest rise continue?

Latest kurtosis is at 2.98. Meridian Bioscience exhibits very low volatility with skewness of -1.3 and kurtosis of 2.98. However, we advise investors to further study Meridian Bioscience technical indicators to make sure all market info is available and is reliable.

Our Bottom Line On Meridian Bioscience

When is the right time to buy or sell Meridian Bioscience? Buying stocks such as Meridian Bioscience isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take over new shares of Meridian nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Meridian Bioscience.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Meridian Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to